BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 16828293)

  • 1. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
    Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT.
    Ganter MT; Dalbert S; Graves K; Klaghofer R; Zollinger A; Hofer CK
    Anesth Analg; 2005 Aug; 101(2):308-314. PubMed ID: 16037133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement.
    Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
    Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
    Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
    J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
    Feindt P; Seyfert UT; Volkmer I; Straub U; Gams E
    Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
    Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
    Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery.
    Patteril M; Stafford-Smith M; Toffaletti JG; Bute BP; Milano CA; Welsby IJ
    Clin Chim Acta; 2005 Jun; 356(1-2):218-24. PubMed ID: 15936321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
    Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
    Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement.
    Machin D; Devine P
    J Extra Corpor Technol; 2005 Sep; 37(3):265-71. PubMed ID: 16350378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
    Jiang L; Yu JF
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
    Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
    J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.